View Clinical Trial (Medical Research Study)

Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT) - NCT00070954-29425(Clinical Trial 118483)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Newark
State:  
NJ
Zip Code: 29425
Conditions: Memory, Short-Term
Purpose: Electroconvulsive therapy (ECT) is an effective treatment for severe or medication-resistant depression and other psychiatric disorders. A common side effect of ECT is problems with short-term memory during treatment. This study will test whether taking ginkgo biloba (GB) prior to and during the course of ECT will lessen the effects of ECT on short-term memory.
Study summary: ECT is a safe and effective modern treatment for severe depression and other psychiatric conditions. An estimated 100,000 treatments occur per year in the United States. ECT's most bothersome adverse effect is memory loss, with all patients receiving ECT experiencing some degree of short-term cognitive impairment. At present there are no known effective pharmacologic treatments to prevent or improve ECT-induced cognitive dysfunction. Preliminary research has shown the herbal preparation GB aids cognitive function and memory in both patients with dementia and in normal volunteers. This study will investigate the utility and safety of GB to minimize the cognitive impairment typically associated with ECT. Participants in this study will be randomly assigned to receive either twice-daily GB or placebo. Participants will begin taking GB or placebo as soon as consent is obtained and baseline testing is completed in order to reach steady-state plasma levels of GB prior to ECT. Patients will undergo cognitive testing at specified intervals following ECT. The final study visit will occur one week after a participant's final ECT treatment.
Criteria: Inclusion Criteria - DSM-IV diagnosis of major depressive episode, unipolar or bipolar, without psychotic features - Receiving ECT for depression - Able to complete detailed neuropsychological testing Exclusion Criteria - Psychotic symptoms - Lifetime history of schizophrenia, schizoaffective disorder, or mental retardation - Diagnosis of anxiety disorder, obsessive-compulsive disorder, or eating disorder within 1 year of study entry - Delirium, dementia, or amnestic disorder - Any active general medical condition or central nervous system disease which could affect cognition or response to treatment - Diagnosis of active substance abuse or dependence within 6 months of study entry - ECT within 6 months of study entry - Known or suspected coagulation disorder - Anticoagulation or antiplatelet medications, including warfarin, aspirin, clopidogrel, and ticlopidine - Thiazide diuretics, selective serotonin reuptake inhibitors, trazodone, antipsychotic medications, herbal medications, or other nutritional supplements - Pregnancy
Study is available at: UMDNJ - NJ Medical School
Newark, NJ 29425
United States

Primary Contact:
Kristen Tobias
Email: tobiaskg@umdnj.edu
Phone: 973-972-8259
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.